Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation

W. Arcese, F. R. Mauro, M. Screnci, G. Alimena, A. P. Iori, M. R. De Guia, F. Lo Coco, E. Montefusco, P. Fazi, F. Mandelli

Research output: Contribution to journalArticlepeer-review

Abstract

20 CML patients with hematological (5 pts) or only cytogenetic (15 pts) relapse occurring after allogeneic BMT have been treated with alpha-2b-interferon (IFN) at a starting dose of 5 x 106 IU/m2, subcutaneously, three times a week. All 5 patients with hematological relapse achieved hematological remission without reduction of bone marrow Ph1-positive cells. With a median follow-up of 43 months (range 6-48) from the hematological relapse, 3 patients are alive and 2 patients died from non-lymphoid blast crisis. 7 out of 15 patients with only cytogenetic relapse remain in hematological remission at a median of 37 months (range 3-45) from cytogenetic relapse, with 2 patients achieving complete cytogenetic remission confirmed at the molecular level by disappearance of the bcr rearranged band. With a median follow-up of 21 months (range 6-46), 8 patients progressed from cytogenetic to hematological relapse: 4 patients died from blast crisis and the other 4 patients are currently alive in chronic phase. For the 15 patients, the actuarial survival from BMT is 71% at 5 years.

Original languageEnglish
Pages (from-to)36-39
Number of pages4
JournalEuropean Journal of Haematology, Supplement
Volume45
Issue number52
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation'. Together they form a unique fingerprint.

Cite this